Astria Therapeutics posted a net loss of $33.1 million in Q2 2025 as operating expenses rose, primarily from clinical trials and stock-based compensation. Despite no revenue, the company ended the quarter with $259.2 million in cash and investments, supported by an upfront payment from its partnership with Kaken.

Astria Therapeutics, Inc. experienced a significant increase in net loss for the first quarter of 2025, primarily driven by higher research and development expenses related to its lead product candidates, navenibart and STAR-0310. The company's cash position remains strong, with sufficient funds to sustain operations into mid-2027.

Astria Therapeutics reported a net loss of $25.6 million for Q4 2024 as the company increased its research and development spending for its lead programs. Despite this, the company maintains a strong cash position, which is expected to support operations into mid-2027. The Phase 3 trial for navenibart is underway, and Astria expects key data readouts in 2025.

Astria Therapeutics reported a net loss of $17.7 million for the third quarter of 2023, with R&D expenses at $13.3 million and G&A expenses at $6.9 million. The company's cash, cash equivalents, and short-term investments totaled $188.8 million as of September 30, 2023, which, combined with proceeds from a recent offering, is expected to fund operations into 2026.

Astria Therapeutics reported its Q4 and full year 2022 financial results. The company's cash, cash equivalents, and short-term investments were $226.4 million as of December 31, 2022. The ALPHA-STAR Phase 1b/2 trial is underway with initial proof-of-concept results anticipated in mid-2024.

Astria Therapeutics reported a net loss of $7.9 million for the third quarter of 2021, with cash and cash equivalents totaling $131.8 million as of September 30, 2021. The company's operating plan is funded through 2023.